Healthcare -
Medical - Diagnostics & Research - NASDAQ - US
$ 2.36
0.426 %
$ 79.9 M
Market Cap
-0.51
P/E
1. INTRINSIC VALUE
Balance Sheet
Inotiv, Inc.
| Current Assets | 163 M |
| Cash & Short-Term Investments | 21.4 M |
| Receivables | 73.6 M |
| Other Current Assets | 68.4 M |
| Non-Current Assets | 618 M |
| Long-Term Investments | 0 |
| PP&E | 237 M |
| Other Non-Current Assets | 380 M |
| Current Liabilities | 119 M |
| Accounts Payable | 33.5 M |
| Short-Term Debt | 15.3 M |
| Other Current Liabilities | 70.2 M |
| Non-Current Liabilities | 492 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 492 M |
EFFICIENCY
Earnings Waterfall
Inotiv, Inc.
| Revenue | 491 M |
| Cost Of Revenue | 380 M |
| Gross Profit | 111 M |
| Operating Expenses | 198 M |
| Operating Income | -86.4 M |
| Other Expenses | 22.5 M |
| Net Income | -109 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Inotiv, Inc.
| Net Income | -109 M |
| Depreciation & Amortization | 57.1 M |
| Capital Expenditures | -22.3 M |
| Stock-Based Compensation | 6.74 M |
| Change in Working Capital | 52.6 M |
| Others | 8.48 M |
| Free Cash Flow | -29.1 M |
Wall Street Analysts Price Targets
Inotiv, Inc.
Wall Street analysts predict an average 1-year price target for NOTV of $6.33 , with forecasts ranging from
a
low of
$4 to a high of $10 .
NOTV Lowest Price Target
Wall Street Target
4 USD
69.49%
NOTV Average Price Target
Wall Street Target
6.33 USD
168.36%
NOTV Highest Price Target
Wall Street Target
10 USD
323.73%
4. DIVIDEND
ANALYSIS
NOTV does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Inotiv, Inc.
Sold
0-3 MONTHS
449 K USD 6
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
728 K USD 4
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Inotiv, Inc. (NOTV) Q1 2025 Earnings Call Transcript
Inotiv, Inc. (NASDAQ:NOTV ) Q1 2025 Results Conference Call February 5, 2025 4:30 PM ET Company Participants Steve Halper - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Dave Windley - Jefferies Operator Good day, everyone, and welcome to today's Inotiv First Quarter Fiscal 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
seekingalpha.com
- 2 months ago
Inotiv, Inc. to Report Fiscal 2025 First Quarter Financial Results and Host Conference Call on Wednesday, February 5, 2025
WEST LAFAYETTE, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, on Wednesday, February 5, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
globenewswire.com
- 2 months ago
Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million
WEST LAFAYETTE, Ind., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised an additional $3.6 million in net proceeds from the optional shares in connection with its previously announced underwritten public offering of common shares. The Company issued the additional 900,000 shares at a price to the public of $4.25 per share. All the shares were offered and sold by the Company. The Company closed on the sale of the 900,000 optional shares of common stock on December 30, 2024.
globenewswire.com
- 3 months ago
Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million
WEST LAFAYETTE, Ind., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised approximately $24.0 million in net proceeds from its underwritten public offering of 6,000,000 common shares at a price to the public of $4.25 per share. All the shares were offered and sold by the Company. The Company closed on the sale of the initial 6,000,000 common shares on December 19, 2024.
globenewswire.com
- 3 months ago
Inotiv, Inc. Launches Proposed Public Offering of Common Shares
WEST LAFAYETTE, Ind., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced commencement of a proposed underwritten public offering of its common shares. All the shares will be offered by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional common shares in an amount of up to 15% of the number of shares sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
globenewswire.com
- 3 months ago
Inotiv, Inc. (NOTV) Q4 2024 Earnings Call Transcript
Inotiv, Inc. (NASDAQ:NOTV ) Q4 2024 Earnings Conference Call December 3, 2024 4:30 PM ET Company Participants Steve Halper - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Operator Good day, everyone, and welcome to today's Inotiv Fiscal 2024 Fourth Quarter Financial Results. At this time, all participants are in a listen-only mode.
seekingalpha.com
- 4 months ago
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2024 and Provides Business Update
— Enhanced liquidity through issuance of Second Lien Notes — Obtained amendment to credit agreement and extended note payable — Fourth quarter fiscal 2024 revenue down 7.3% to $130.4 million — Full year fiscal 2024 revenue down 14.3% to $490.7 million — Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q4 FY 2024”) and twelve months ("FY 2024") ended September 30, 2024.
globenewswire.com
- 4 months ago
Inotiv Ranked Number 138 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Acquiring and Developing Services and Resources to Build a Full Service, Customer-Focused CRO has Fueled 847% Revenue Growth Acquiring and Developing Services and Resources to Build a Full Service, Customer-Focused CRO has Fueled 847% Revenue Growth
globenewswire.com
- 4 months ago
Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024
WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, on Tuesday, December 3, 2024, after the close of the stock market.
globenewswire.com
- 4 months ago
Inotiv, Inc. Amends Its Credit Agreement and Secures Additional Liquidity
WEST LAFAYETTE, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, has amended certain terms of its Credit Agreement. In addition, Inotiv has closed the sale of $22.6 million aggregate principal amount of 15% Senior Secured Second Lien PIK Notes due February 2027 (the “Second Lien Notes”), and warrants to purchase common shares, to certain investors in a private offering.
globenewswire.com
- 6 months ago
Inotiv to Participate in the 8th Annual Lake Street Best Ideas Growth Conference
WEST LAFAYETTE, Ind., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., Inotiv's President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the 8th Annual Lake Street Best Ideas Growth Conference on Thursday, September 12, 2024, in New York City.
globenewswire.com
- 7 months ago
Inotiv, Inc. (NOTV) Q3 2024 Earnings Call Transcript
Inotiv, Inc. (NASDAQ:NOTV ) Q3 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Bob Yedid - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer John Sagartz - Chief Strategy Officer Conference Call Participants Matt Hewitt - Craig-Hallum Nelson Cox - Lake Street Capital Markets Dave Windley - Jefferies Eric Coldwell - Baird Operator Good day, everyone and welcome to this Inotiv Third Quarter Earnings Conference Call. [Operator Instructions] And it's now my pleasure to turn the floor over to Mr.
seekingalpha.com
- 8 months ago
8. Profile
Summary
Inotiv, Inc. NOTV
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 79.9 M
Dividend Yield
0.00%
Description
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Contact
2701 Kent Avenue, West Lafayette, IN, 47906-1382
https://www.inotivco.com
IPO
Date
Nov. 25, 1997
Employees
1977
Officers
Dr. John E. Sagartz D.V.M., DiplomateACVP, Ph.D.
Chief Strategy Officer & Director
Ms. Beth A. Taylor CPA
Senior Vice President of Finance & Chief Financial Officer
Ms. Lizanne Muller
Group President of RMS
Ms. Andrea Castetter
SVice President of General Counsel, Corporate Secretary & Chief Compliance Officer
Mr. John Gregory Beattie DSA
Chief Operating Officer of DSA
Dr. Adrian Hardy Ph.D.
Chief Commercial Officer
Mr. Robert W. Leasure Jr.
President, Chief Executive Officer & Director
Mr. Brennan Freeman
Vice President of Finance, Principal Accounting Officer & Corporate Controller
Mr. Jeffrey Arthur Krupp
Chief Human Resources Officer